Meningitis Etiology
The causative pathogens of bacterial meningitis are highly age-dependent: neonates are predominantly infected by Group B Streptococcus (58%) and E. coli (21%), children beyond the neonatal period primarily by S. pneumoniae and N. meningitidis (with serogroup B now dominant), and adults overwhelmingly by S. pneumoniae, with L. monocytogenes becoming the third most common pathogen in elderly and immunocompromised patients. 1
Age-Stratified Etiology
Neonates (0-6 weeks)
The neonatal period shows distinct pathogen distribution based on timing:
- Early neonatal meningitis (first week): Vertical transmission via birth canal
- Late neonatal meningitis (weeks 2-6): Nosocomial or horizontal transmission
Primary pathogens (accounting for two-thirds of cases):
- Streptococcus agalactiae (Group B Streptococcus): 58% of cases
- Escherichia coli: 21% of cases
- Listeria monocytogenes: Only 2% (historically overestimated)
- Streptococcus pneumoniae: 4% (rare in this age group) 1
Critical caveat: Despite intrapartum antibiotic prophylaxis implementation, GBS incidence has not declined as expected in recent surveillance data, with some regions showing increased rates in the 2000s 1.
Children Beyond Neonatal Age
The landscape has been dramatically reshaped by vaccination programs:
Current dominant pathogens:
- Streptococcus pneumoniae: 22.5-41.1% (now as common as meningococcal disease)
- Neisseria meningitidis: Primarily serogroup B (up to 47% in European children aged 1-5 years)
- Haemophilus influenzae type b: Virtually eliminated post-vaccination; rare cases from non-type b serotypes or unvaccinated children 1
The introduction of conjugate vaccines (Hib, MenC, PCV7/10/13) has fundamentally altered epidemiology, with pneumococcal meningitis now rivaling meningococcal disease in frequency 1.
Adults
S. pneumoniae dominates, causing the majority of adult bacterial meningitis cases, with regional variation from 9.6% (Western Pacific) to 75.2% (Africa) 2.
Age-stratified adult patterns:
- Adolescents/young adults: N. meningitidis (predominantly serogroup B)
- Older adults (≥65 years):
Uncommon pathogens (1-2% of cases):
- H. influenzae: Associated with otitis/sinusitis
- Staphylococcus aureus: Associated with endocarditis 1
Global and Regional Variations
The 2018 global meta-analysis reveals significant geographic heterogeneity 2:
- S. pneumoniae and N. meningitidis remain predominant across all regions, accounting for 25.1-41.2% and 9.1-36.2% of cases respectively
- Africa: Highest pneumococcal burden (41.1% in children, 75.2% in adults); E. coli and S. pneumoniae co-dominate neonatal meningitis (17.7% and 20.4%)
- Europe: N. meningitidis peaks at 47% in children aged 1-5 years; lowest pneumococcal rates (22.5% in children)
Emerging Trends and Concerns
Vaccine Impact and Serotype Replacement
Post-PCV introduction, serotype replacement toward non-vaccine strains has emerged as a major concern, potentially limiting long-term vaccine effectiveness 4, 1. Continuous surveillance remains critical.
Antimicrobial Resistance
Reduced susceptibility to penicillin and third-generation cephalosporins in S. pneumoniae varies considerably across European countries, necessitating region-specific empiric regimens 4.
Recent Epidemiologic Shifts
The 2012-2021 Swiss nationwide study documented:
- Overall CNS infection incidence increased from 22 to 34 per 100,000 (2012-2019)
- Marked decline in 2020-2021 driven by ~65% reduction in pneumococcal and ~90% reduction in enteroviral meningitis 3
Non-Bacterial Pathogens
Recent GBD 2023 data highlight emerging importance of:
- Non-polio enteroviruses (leading cause of incident cases globally)
- Drug-resistant fungi and Candida spp 5
Risk Factors for Specific Pathogens
L. monocytogenes specifically targets:
- Age ≥65 years
- Immunocompromised states
- Pregnancy 1
Poor prognostic indicators (regardless of pathogen):
- Age >65 years
- Coexisting pneumonia
- Platelet count <150×10⁹/L
- CSF pressure ≥200 mmH₂O (elderly)
- Temperature ≥38.5°C (non-elderly)
- Pulmonary infection 6, 7
Clinical Implications
Empiric therapy must account for:
- Patient age (primary determinant)
- Local resistance patterns
- Vaccination status
- Immunocompromise/comorbidities
- Geographic location
The four WHO-defined preventable pathogens (S. pneumoniae, N. meningitidis, H. influenzae, Group B Streptococcus) contributed to 98,700 deaths and 594,000 cases globally in 2023, underscoring the continued need for vaccination expansion and health system strengthening 5.